Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating…
Category: Health Issues
Laureate and ARIUS Cooperation
Laureate Announces Second Manufacturing Agreement with Cytheris
Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for…
Laureate Pharma Agreement with Alopexx Pharmaceuticals
Laureate To Manufacture Alopexx’s Product Candidate On April 10, 2008, Laureate Pharma, Inc., a large company engaged in biopharmaceutical development and protein production reported that it has concluded a contract manufacturing agreement with Alopexx Pharmaceuticals on the production of Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and also for fighting Staphylococcus aureus infections. The details of the agreement were not announced. “We are happy that Laureate…